ARDS vs. SCPS, EVLO, CMRA, GNCAQ, GNCA, STAB, CLVR, EFTR, ONCSQ, and PXMD
Should you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Statera Biopharma (STAB), Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), OncoSec Medical (ONCSQ), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry.
Aridis Pharmaceuticals vs. Its Competitors
Scopus BioPharma (NASDAQ:SCPS) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.
Scopus BioPharma has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 12.09, meaning that its share price is 1,109% more volatile than the S&P 500.
Scopus BioPharma has higher earnings, but lower revenue than Aridis Pharmaceuticals.
9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Scopus BioPharma had 2 more articles in the media than Aridis Pharmaceuticals. MarketBeat recorded 2 mentions for Scopus BioPharma and 0 mentions for Aridis Pharmaceuticals. Scopus BioPharma's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.
Summary
Aridis Pharmaceuticals beats Scopus BioPharma on 4 of the 6 factors compared between the two stocks.
Get Aridis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aridis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ARDS) was last updated on 7/3/2025 by MarketBeat.com Staff
Free ARDS Stock Alerts